Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$49,658.00
Jan 27, 2026
For-profit organization
ICAP-2025 – Japan – International Co-Innovation Action Plan
1039286
This project under the International Co-Innovation Action Program (ICAP) will prepare the firm to engage in future international co-innovation initiatives in Japan.
$12,850.50
Jun 4, 2025
For-profit organization
9397-2677 Québec inc.-2025-2026-1031657
1031657
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.
$30,000.00
Jun 2, 2025
For-profit organization
YOUTH - Improvement of the technological platform.
1031820
The aim of the project is to identify the optimal doses for five new treatments on human tumours explants by conducting efficacy tests on spheroids from three different cell lines.
$99,900.00
Apr 15, 2024
For-profit organization
Development of an application for tissue microchip measurement.
1017172
The main human-derived tumor models (cell lines, xenografts and organoids) do not preserve the immune cells of the tumor from which they are derived. This limits the ability to effectively predict the effect of cancer immunotherapies in humans, and the ability to de-risk clinical validation. This project aims to characterize the immune microenvironment of human tumor explants and demonstrate its ability to measure an immune and cytotoxic response to a treatment applied ex vivo.
$30,000.00
Oct 9, 2023
For-profit organization
YOUTH - Development of an ex vivo human tumor model for the development of immunotherapies
1010568
This project aims to develop an ex vivo platform for the development of cancer immunotherapies and the discovery of predictive biomarkers. The project includes the development of protocols for 1) preserving/transporting human tumor samples and 2) maintaining the ex vivo viability of a new type of cancer.
$28,246.00
Apr 4, 2022
For-profit organization
Market study and marketing strategy of a platform for the development of drugs and diagnostic tools.
989115
The project aims to develop the market strategy for two new market segments contemplated for the next few years, among other things, to confirm the value proposition for these two different segments.
$99,500.00
Sep 15, 2021
For-profit organization
Ex vivo use of mouse tumor microdissections for preclinical development of cancer immunotherapies
979207
The project aims to establish the utility of the technology to test, in a single ex vivo experiment, several combinations of immunotherapies to identify the most effective one, and to screen murine tumor models to identify the best preclinical model to study a given immunotherapy.